Bristol Myers Squibb CTLA-4 fusion protein has won priority review qualification from FDA
On August 23, Bristol Myers Squibb $BMY announced that orencia’s listing application for the prevention of moderate / severe acute graft-versus-host disease (aGVHD) in patients over 6 years old receiving unrelated hematopoietic stem cell transplantation was granted priority review qualification by FDA.
Hematopoietic stem cell transplantation is an effective method for the treatment of invasive leukemia and other malignant hematoma. However, GVHD occurs when donor T cells recognize the patient’s healthy cells as foreign objects and begin to attack. This activation of T cells can lead to severe immune-mediated tissue damage in the host. Skin, liver and gastrointestinal tract are the most common targets. Orencia is a fusion protein composed of CTLA-4 and FC, which can bind and inhibit protein targets involved in CO stimulation, so as to inhibit T cell activation.